Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients.
Kuerten S, Lanz TV, Lingampalli N, Lahey LJ, Kleinschnitz C, Mäurer M, Schroeter M, Braune S, Ziemssen T, Ho PP, Robinson WH, Steinman L. Kuerten S, et al. Among authors: maurer m. Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21512-21518. doi: 10.1073/pnas.2011249117. Epub 2020 Aug 18. Proc Natl Acad Sci U S A. 2020. PMID: 32817492 Free PMC article.
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O. Warnke C, et al. Among authors: maurer m. Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8. Ann Neurol. 2014. PMID: 24729444 Free PMC article.
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC. Warnke C, et al. Among authors: maurer m. Mult Scler. 2015 Jul;21(8):1036-44. doi: 10.1177/1352458514556296. Epub 2014 Nov 12. Mult Scler. 2015. PMID: 25392339
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP. Ziemssen T, et al. Among authors: maurer m. BMC Neurol. 2016 Jul 12;16:98. doi: 10.1186/s12883-016-0625-0. BMC Neurol. 2016. PMID: 27405225 Free PMC article.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA. Huhn K, et al. Among authors: maurer m. J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25. J Neurol. 2018. PMID: 29696498
2,536 results